Hemochromatosis Enhances Tumor Progression via Upregulation of Intracellular Iron in Head and Neck Cancer

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Lenarduzzi, Michelle ^a,b   Hui, Angela B Y ^a   Yue, Shijun ^a   Ito, Emma ^a   Shi, Wei ^a   Williams, Justin ^a   Bruce, Jeff ^a,b   Sakemura Nakatsugawa, Noriko ^a   Xu, Wei ^a,d   Schimmer, Aaron ^a,b   Liu, Fei Fei ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CICLOPIROXOLAMINE; DNA; HEPCIDIN; IRON; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMOCHROMATOSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HEMOCHROMATOSIS; HUMANS; IRON; UP-REGULATION;

EID: 84883200039     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074075     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
2. Ferlay J SH, Bray F, Forman D, Mathers C, Parkin DM, (2008) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10.
3. Leemans CR, Braakhuis BJ, Brakenhoff RH, (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22. doi:10.1038/nrc2982. PubMed: 21160525.
4. Song S, Christova T, Perusini S, Alizadeh S, Bao RY, et al. (2011) Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res 71: 7628-7639. doi:10.1158/0008-5472.CAN-11-2745. PubMed: 22009536.
5. Hentze MW, Muckenthaler MU, Galy B, Camaschella C, (2010) Two to tango: regulation of Mammalian iron metabolism. Cell 142: 24-38. doi:10.1016/j.cell.2010.06.028. PubMed: 20603012.
6. Feder JN, Tsuchihashi Z, Irrinki A, Lee VK, Mapa FA, et al. (1997) The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 272: 14025-14028. doi:10.1074/jbc.272.22.14025. PubMed: 9162021.
7. West AP Jr., Giannetti AM, Herr AB, Bennett MJ, Nangiana JS, et al. (2001) Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites. J Mol Biol 313: 385-397. doi:10.1006/jmbi.2001.5048. PubMed: 11800564.
8. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, et al. (2009) Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 9: 217-227. doi:10.1016/j.cmet.2009.01.010. PubMed: 19254567.
9. Schmidt PJ, Fleming MD, (2012) Transgenic HFE-dependent induction of hepcidin in mice does not require transferrin receptor-2. Am J Hematol 87: 588-595. doi:10.1002/ajh.23173. PubMed: 22460705.
10. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093. doi:10.1126/science.1104742. PubMed: 15514116.
11. Drakesmith H, Sweetland E, Schimanski L, Edwards J, Cowley D, et al. (2002) The hemochromatosis protein HFE inhibits iron export from macrophages. Proc Natl Acad Sci U S A 99: 15602-15607. doi:10.1073/pnas.242614699. PubMed: 12429850.
12. Davies PS, Enns CA, (2004) Expression of the hereditary hemochromatosis protein HFE increases ferritin levels by inhibiting iron export in HT29 cells. J Biol Chem 279: 25085-25092. doi:10.1074/jbc.M400537200. PubMed: 15044462.
13. Pietrangelo A, (2010) Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 139: 393-408.e391-392 doi:10.1053/j.gastro.2010.06.013. PubMed: 20542038.
14. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, et al. (2001) Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 33: 647-651. doi:10.1053/jhep.2001.22506. PubMed: 11230745.
15. Pekkola-Heino K, Kulmala J, Grenman R, (1992) Sublethal damage repair in squamous cell carcinoma cell lines. Head Neck 14: 196-199. doi:10.1002/hed.2880140306. PubMed: 1587736.
16. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, et al. (2007) Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 29: 163-188. doi:10.1002/hed.20478. PubMed: 17312569.
17. Lenarduzzi M, Hui AB, Alajez NM, Shi W, Williams J, et al. (2013) MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1. PLOS ONE 8: e53765. doi:10.1371/journal.pone.0053765. PubMed: 23335975.
18. Ito E, Yue S, Moriyama EH, Hui AB, Kim I, et al. (2011) Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci Transl Med 3: 67ra67. PubMed: 21270338.
19. Hui AB, Yue S, Shi W, Alajez NM, Ito E, et al. (2009) Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clin Cancer Res 15: 3716-3724. doi:10.1158/1078-0432.CCR-08-2790. PubMed: 19470731.
20. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6. PubMed: 15068665.
21. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, et al. (2004) Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 64: 55-63. doi:10.1158/0008-5472.CAN-03-2144. PubMed: 14729608.
22. Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, et al. (2007) Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 67: 4605-4619. doi:10.1158/0008-5472.CAN-06-3619. PubMed: 17510386.
23. Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, et al. (2004) Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23: 2484-2498. doi:10.1038/sj.onc.1207345. PubMed: 14676830.
24. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442. doi:10.1038/415436a. PubMed: 11807556.
25. Jones J, Otu H, Spentzos D, Kolia S, Inan M, et al. (2005) Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11: 5730-5739. doi:10.1158/1078-0432.CCR-04-2225. PubMed: 16115910.
26. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, et al. (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404. doi:10.1158/2159-8290.CD-12-0095 PubMed: 22588877.
27. Hower V, Mendes P, Torti FM, Laubenbacher R, Akman S, et al. (2009) A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst 5: 422-443. doi:10.1039/b816714c. PubMed: 19381358.
28. Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, et al. (2007) Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13: 4964-4973. doi:10.1158/1078-0432.CCR-07-1041. PubMed: 17785546.
29. Bayeva M, Khechaduri A, Puig S, Chang HC, Patial S, et al. (2012) mTOR regulates cellular iron homeostasis through tristetraprolin. Cell Metab 16: 645-657. doi:10.1016/j.cmet.2012.10.001. PubMed: 23102618.
30. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, et al. (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13: 399-408. doi:10.1038/ng0896-399. PubMed: 8696333.
31. De Domenico I, Ward DM, Langelier C, Vaughn MB, Nemeth E, et al. (2007) The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell 18: 2569-2578. doi:10.1091/mbc.E07-01-0060. PubMed: 17475779.
32. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr., Kute T, et al. (2010) Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2: 43ra56. PubMed: 20686179.
33. Ward DG, Roberts K, Brookes MJ, Joy H, Martin A, et al. (2008) Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol 14: 1339-1345. doi:10.3748/wjg.14.1339. PubMed: 18322945.
34. Kamai T, Tomosugi N, Abe H, Arai K, Yoshida K, (2009) Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer 9: 270. doi:10.1186/1471-2407-9-270. PubMed: 19656379.
35. Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, et al. (2008) Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 14: 3262-3267. doi:10.1158/1078-0432.CCR-07-4153. PubMed: 18519751.
36. Faulk WP, Hsi BL, Stevens PJ, (1980) Transferrin and transferrin receptors in carcinoma of the breast. Lancet 2: 390-392. PubMed: 6105517.
37. Wada S, Noguchi T, Takeno S, Kawahara K, (2006) PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma. Ann Surg Oncol 13: 961-966. doi:10.1245/ASO.2006.08.006. PubMed: 16788758.
38. Kondo K, Noguchi M, Mukai K, Matsuno Y, Sato Y, et al. (1990) Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. Chest 97: 1367-1371. doi:10.1378/chest.97.6.1367. PubMed: 2189695.
39. Güner G, Kirkali G, Yenisey C, Töre IR, (1992) Cytosol and serum ferritin in breast carcinoma. Cancer Lett 67: 103-112. doi:10.1016/0304-3835(92)90132-F. PubMed: 1483258.
40. Coffman LG, Parsonage D, D'Agostino R Jr., Torti FM, Torti SV, (2009) Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A 106: 570-575. doi:10.1073/pnas.0812010106. PubMed: 19126685.
41. Vaughn CB, Weinstein R, Bond B, Rice R, Vaughn RW, et al. (1987) Ferritin content in human cancerous and noncancerous colonic tissue. Cancer Invest 5: 7-10. doi:10.3109/07357908709020300. PubMed: 3580949.
42. Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, et al. (2011) An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 71: 6728-6737. doi:10.1158/0008-5472.CAN-11-1870. PubMed: 21875943.
43. Montosi G, Paglia P, Garuti C, Guzman CA, Bastin JM, et al. (2000) Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. Blood 96: 1125-1129. PubMed: 10910932.
44. Bystrom LM, Guzman ML, Rivella S, (2013) Iron and Reactive Oxygen Species: Friends or Foes of Cancer Cells? Antioxid Redox Signal.
45. Ziech D, Franco R, Pappa A, Panayiotidis MI, (2011) Reactive oxygen species (ROS)--induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res 711: 167-173. doi:10.1016/j.mrfmmm.2011.02.015. PubMed: 21419141.
46. Maehata Y, Ozawa S, Kobayashi K, Kato Y, Yoshino F, et al. (2010) Reactive oxygen species (ROS) reduce the expression of BRAK/CXCL14 in human head and neck squamous cell carcinoma cells. Free Radic Res 44: 913-924. doi:10.3109/10715762.2010.490836. PubMed: 20815772.
47. Rhee CS, Sen M, Lu D, Wu C, Leoni L, et al. (2002) Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 21: 6598-6605. doi:10.1038/sj.onc.1205920. PubMed: 12242657.
48. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, et al. (2009) Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 114: 3064-3073. doi:10.1182/blood-2009-03-209965. PubMed: 19589922.
49. Nagler RM, Eichen Y, Nagler A, (2001) Redox metal chelation ameliorates radiation-induced bone marrow toxicity in a mouse model. Radiat Res 156: 205-209. doi:10.1667/0033-7587(2001)156[0205:RMCARI]2.0.CO;2. PubMed: 11448242.
50. Lui GY, Obeidy P, Ford SJ, Tselepis C, Sharp DM, et al. (2013) The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol 83: 179-190. doi:10.1124/mol.112.081893. PubMed: 23074173.